Cargando…

Exploring the Pathological Mechanism of Bladder Cancer Based on Tumor Mutational Burden Analysis

Although immunotherapy has progressed in the treatment of bladder cancer, some patients still have poor prognosis. New therapeutic targets are eager to be discovered to improve the outcomes of bladder cancer. With the development of high-throughput sequencing and tumor profiling, potential tumor bio...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ma, Yao, Feng, Xiao-Fei, Yang, Wan-Xia, You, Chong-Ge
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2019
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6732589/ https://www.ncbi.nlm.nih.gov/pubmed/31534952 http://dx.doi.org/10.1155/2019/1093815

Ejemplares similares

Radiomic assessment as a method for predicting tumor mutation burden (TMB) of bladder cancer patients: a feasibility study
por: Tang, Xin, et al.
Publicado: (2021)

Mining TCGA database for tumor mutation burden and their clinical significance in bladder cancer
por: Lv, Jia, et al.
Publicado: (2020)

Identification and validation of RB1 as an immune-related prognostic signature based on tumor mutation burdens in bladder cancer
por: Liu, Ning, et al.
Publicado: (2022)

EP300 mutation is associated with tumor mutation burden and promotes antitumor immunity in bladder cancer patients
por: Zhu, Gongmin, et al.
Publicado: (2020)

Exploration of the Associations of lncRNA Expression Patterns with Tumor Mutation Burden and Prognosis in Colon Cancer
por: Ding, Chengsheng, et al.
Publicado: (2021)

Exploration of the relationship between tumor mutation burden and immune infiltrates in colon adenocarcinoma
por: Ouyang, Rong, et al.
Publicado: (2021)

Exploration of the Tumor Mutational Burden as a Prognostic Biomarker and Related Hub Gene Identification in Prostate Cancer
por: Wang, Licheng, et al.
Publicado: (2021)

A Prognostic Model for Predicting Tumor Mutation Burden and Tumor-Infiltrating Immune Cells in Bladder Urothelial Carcinoma
por: Wang, Chengbang, et al.
Publicado: (2022)

Tumor mutational burden is associated with poor outcomes in diffuse glioma
por: Wang, Lihong, et al.
Publicado: (2020)

Identification of NTRK3 as a potential prognostic biomarker associated with tumor mutation burden and immune infiltration in bladder cancer
por: Zhang, Zhao, et al.
Publicado: (2021)

Tumor mutation burden testing: a survey of the International Quality Network for Pathology (IQN Path)
por: Fenizia, Francesca, et al.
Publicado: (2021)

LRP1B mutation associates with increased tumor mutation burden and inferior prognosis in liver hepatocellular carcinoma
por: Yu, Ge, et al.
Publicado: (2022)

A Muscle-Invasive Bladder Cancer Patient With High Tumor Mutational Burden and RB1 Mutation Achieved Bladder Preservation Following Chemotherapy Combined With Immunotherapy: A Case Report
por: Cao, Chuanzhen, et al.
Publicado: (2021)

Identification of a Gene Prognostic Model of Gastric Cancer Based on Analysis of Tumor Mutation Burden
por: Ma, Weijun, et al.
Publicado: (2021)

USH2A Mutation is Associated With Tumor Mutation Burden and Antitumor Immunity in Patients With Colon Adenocarcinoma
por: Sun, Yuanyuan, et al.
Publicado: (2021)

Identification of tumor mutation burden-related hub genes and the underlying mechanism in melanoma
por: Zhang, Chuan, et al.
Publicado: (2021)

MRI characteristics and correlation with pathology of an unusual inflammatory myofibroblastic tumor of the bladder
por: Ma, Wanling, et al.
Publicado: (2022)

Spatial heterogeneity and organization of tumor mutation burden with immune infiltrates within tumors based on whole slide images correlated with patient survival in bladder cancer
por: Xu, Hongming, et al.
Publicado: (2022)

Defining muscle-invasive bladder cancer immunotypes by introducing tumor mutation burden, CD8+ T cells, and molecular subtypes
por: Chen, Zihao, et al.
Publicado: (2021)

Canine tumor mutational burden is correlated with TP53 mutation across tumor types and breeds
por: Alsaihati, Burair A., et al.
Publicado: (2021)

Immunotherapy and tumor mutational burden in cancer patients with liver metastases: A meta and real word cohort analysis
por: Wu, Rui-Yan, et al.
Publicado: (2023)

Complete Pathological Response to Neoadjuvant Chemoimmunotherapy in a Patient With Metastatic Intrahepatic Cholangiocarcinoma With High Tumor Mutational Burden
por: Abudalou, Mohammad, et al.
Publicado: (2021)

Racial disparities in patient survival and tumor mutation burden, and the association between tumor mutation burden and cancer incidence rate
por: Zhang, Wensheng, et al.
Publicado: (2017)

Tumor mutation burden: from comprehensive mutational screening to the clinic
por: Galuppini, Francesca, et al.
Publicado: (2019)

Urothelial Bladder Carcinomas with High Tumor Mutation Burden Have a Better Prognosis and Targetable Molecular Defects beyond Immunotherapies
por: Voutsadakis, Ioannis A.
Publicado: (2022)

Correlation between LRP1B Mutations and Tumor Mutation Burden in Gastric Cancer
por: Hu, Sizhe, et al.
Publicado: (2021)

Association Analyses of TP53 Mutation With Prognosis, Tumor Mutational Burden, and Immunological Features in Acute Myeloid Leukemia
por: Wen, Xiang-mei, et al.
Publicado: (2021)

ecTMB: a robust method to estimate and classify tumor mutational burden
por: Yao, Lijing, et al.
Publicado: (2020)

Exploration of immune-related genes in high and low tumor mutation burden groups of chromophobe renal cell carcinoma
por: Li, Lei, et al.
Publicado: (2020)

The Clinical Implications of Tumor Mutational Burden in Osteosarcoma
por: Xie, Lu, et al.
Publicado: (2021)

Multiomics analysis of tumor mutational burden across cancer types
por: Li, Lin, et al.
Publicado: (2021)

Tumor Mutational Burden Associated With Response to Hyperthermic Intraperitoneal Chemotherapy
por: Zeng, Lisi, et al.
Publicado: (2022)

Tumor mutation burden and recurrent tumors in hereditary lung cancer
por: Hsu, Yi‐Chiung, et al.
Publicado: (2019)

FAT3 Mutation Is Associated With Tumor Mutation Burden and Poor Prognosis in Esophageal Cancer
por: Guo, Zixin, et al.
Publicado: (2021)

Association of LRP1B Mutation With Tumor Mutation Burden and Outcomes in Melanoma and Non-small Cell Lung Cancer Patients Treated With Immune Check-Point Blockades
por: Chen, Hao, et al.
Publicado: (2019)

Decoding tumor mutation burden and driver mutations in early stage lung adenocarcinoma using CT‐based radiomics signature
por: Wang, Xiaoxiao, et al.
Publicado: (2019)

Characterization of Frequently Mutated Cancer Genes and Tumor Mutation Burden in Chinese Breast Cancer
por: Xiao, Weikai, et al.
Publicado: (2021)

Identification of gene expression profiles and immune cell infiltration signatures between low and high tumor mutation burden groups in bladder cancer
por: Wu, Zonglong, et al.
Publicado: (2020)

Tumor mutational burden standardization initiatives: Recommendations for consistent tumor mutational burden assessment in clinical samples to guide immunotherapy treatment decisions
por: Stenzinger, Albrecht, et al.
Publicado: (2019)

Beyond Tumor Mutation Burden: Tumor Neoantigen Burden as a Biomarker for Immunotherapy and Other Types of Therapy
por: Wang, Peipei, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_gmdeck3eil8k01ctb06hptbdf5